Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market Share

Report ID: GMI1939
Published Date: Aug 2021
Report Format: PDF

Download Free Sample

Pulmonary Arterial Hypertension Market Share

Some of the major companies operating in the market are:

Bayer AG
Eli Lilly and Company
Gilead Sciences, Inc
GlaxoSmithKline plc
Johnson & Johnson

These major participants are adopting strategic formulations such as new product development & commercialization, commercial expansion, distribution agreements for business expansion. Moreover, these leaders are investing heavily in developing products, thereby fuelling the revenue generation.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Pulmonary arterial hypertension market size had surpassed USD 6.6 billion in 2020 and will witness a CAGR of 6% through 2027.

Endothelin receptor antagonist segment will observe a CAGR of 5.5% through 2027 as the drug is highly recommended to reverse the damage of heart & lungs and slow the progression of PAH.

Oral segment had captured a revenue share of over 69% in 2020 owing to higher preference for this route of administration due to the convenience and non-invasiveness.

U.S. dominated North America pulmonary arterial hypertension market and will record a valuation of over USD 6.25 billion by 2027 owing to increasing hospital admissions for PAH and growing supportive government initiatives.

Germany held 10% of the market share in 2020 and will record over USD 194 million by 2027 owing to rising prevalence of PAH in the country.